![Gert Adam Irma Thijs](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gert Adam Irma Thijs
Keine laufenden Positionen mehr
Karriereverlauf von Gert Adam Irma Thijs
Ehemalige bekannte Positionen von Gert Adam Irma Thijs
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Gründer | 28.08.2009 | 11.05.2012 |
Corporate Officer/Principal | 01.01.2005 | 11.05.2012 |
Ausbildung von Gert Adam Irma Thijs
Université Catholique de Louvain | Undergraduate Degree |
Statistik
International
Belgien | 3 |
Operativ
Founder | 1 |
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Health Technology |
- Börse
- Insiders
- Gert Adam Irma Thijs
- Erfahrung